https://www.thehindubusinessline.com/economy/agri-business/feed-report-flags-gaps-in-cooperatives-digital-access-for-marginal-farmers/article70433120.ece Copy A ...

December 22 : Lucknow: On Sunday, Chief Minister Yogi Adityanath inaugurated the Youth Cooperative Conference and UP Cooperative Expo 2025 at Jupiter Hall, Indira Gandhi Pratishthan, as part of the ...

Uttar Pradesh moving towards a “one district, one cooperative bank” framework, says chief minister Yogi Adityanath, accuses previous government of devastating the cooperative sector Less than 15 ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for the next 5 years. On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb to $57 from $51, ...

The U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma (MZL) who have failed treatment or relapsed ...

Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi). "Patients living with marginal zone lymphoma .

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy in the indication, as well as the first CAR-T to reach the market for five ...

“The FDA approval of Breyanzi for relapsed or refractory marginal zone lymphoma further solidifies it as the leading CD19-directed CAR T cell therapy covering the broadest range of B-cell malignancies ...

For almost a year, a mobile laboratory has been parked in a corner of Borussia Dortmund’s training ground. It has a small group of full-time technicians inside and equipment costing millions of Euros.

The FDA has approved lisocabtagene maraleucel (Breyanzi, Bristol-Myers Squibb) for relapsed or refractory marginal zone lymphoma (MZL) in adults after at least two prior lines of systemic therapy.